Navigation Links
Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease
Date:6/10/2013

's disease subjects at 31 study sites in the US (NCT 01397422).  The study's primary efficacy analysis compared ADS-5102 to placebo for reduction in LID over 8 weeks as assessed by the Unified Dyskinesia Rating Scale (UDysRS).  Secondary efficacy outcome measures included changes in a standardized PD diary, including "on time" without troublesome dyskinesia; overall PD clinical status as assessed by the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS); and fatigue measured using the Fatigue Severity Scale.  The EASED trial also included an assessment of dose response for ADS-5102.  The study enrolled male and female subjects aged 30 to 85 years who had Parkinson's disease and were experiencing troublesome LID.  Study participants were randomized to receive a low, medium or high dose of ADS-5102 or placebo once-nightly for eight weeks with a two-week safety follow-up.  Safety measures included adverse events and routine safety laboratory tests that were reviewed during the study by an independent data monitoring committee.  Additional information about the study will be presented in the poster.

About ADS-5102 (Nurelin™)
ADS-5102 is a proprietary, investigational, extended-release formulation of amantadine HCl in development for the treatment of central nervous system (CNS) disorders, including LID in Parkinson's disease.  Designed for once-nightly administration, ADS-5102's unique "chronotherapeutic" profile is characterized by a slow increase in amantadine plasma concentrations, expected to result in high plasma concentrations during the daytime hours when LID can be troublesome, and low plasma concentrations overnight.  The low overnight amantadine plasma concentration may reduce the insomnia, sleep disturbances, and vivid dreams occasionally associated with amantadine.  Due to its altered pharmacokinetic profile, ADS-5102 is being investigated in clinical studies at daily dose strengths gre
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
2. Access Pharmaceuticals Signs US License Agreement With AMAG Pharmaceuticals For MuGard
3. HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease
4. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
9. Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013
10. Ampio Pharmaceuticals to List on the NYSE MKT
11. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
(Date:6/1/2015)... , June 1, 2015 /CNW Telbec/ -  Ergoresearch Ltd ... and known under the « Équilibre, orthèses et ... Ended on March 31, 2015. All dollar amounts in the ... for the third quarter of fiscal year 2015 ended this ... to revenues of $ 3,823,151 for the quarter ended March ...
(Date:6/1/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a ... therapies in new orphan drug indications, announced that it ... live webcast today, June 1, 2015, at 5:30 p.m. ... data from its Phase I/II study of VAL-083 ...
Breaking Medicine Technology:OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 2DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 3DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 4
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that ... Drugs Advisory Committee (ODAC) recommended approval of Afinitor® ... advanced neuroendocrine tumors (NET) of pancreatic origin. ... data from the everolimus RADIANT (RAD001 In Advanced ...
... 12, 2011 MSA (NYSE: MSA ), the ... that protect people,s health and safety, announced today that it ... via the Internet on Thursday, April 28, 2011 at 10:00 ... Investors and interested parties will have the opportunity ...
Cached Medicine Technology:Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10MSA Schedules First Quarter Earnings Webcast 2
(Date:6/2/2015)... Join us for a new event in Westwood, New Jersey—the ... , who overcame her brain aneurysm during the summer of ... awareness and funds for brain aneurysm research. , Rhonda ... will be one less case of someone suffering from a ... the 1st Anniversary Awareness Walk in Honor of Rhonda ...
(Date:6/2/2015)... Vancouver, B.C., Canada (PRWEB) June 02, 2015 ... publisher of audit, compliance and risk solutions ... a new online risk management effectiveness gap-improvement program. ... the effect of uncertainty on objectives. Organizations not ... they improve their capabilities to do this (risk ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Lynn Lester as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... exclusively for professional women, boasting more than 700,000 members ... to honor Lynn Lester with this prestigious award,” said ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Lourinda Willey as a 2015-2016 ... Circle. She is recognized with this prestigious distinction for ... is the nation’s leading networking organization exclusively for professional ... operating Local Chapters. , "I’m pleased to present Lourinda ...
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Selma Tansey as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... exclusively for professional women, boasting more than 700,000 members ... to present Selma with this important honor," said NAPW ...
Breaking Medicine News(10 mins):Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2
... in alpha-linoleic acid reduced cardiac events in Asian people at ... in South Asian people, especially if they move to the ... by conventional risk factors,// like diabetes and high blood pressure. ... with the effect of a Mediterranean type diet on cardiac ...
... to a major medical study by researchers it is ... The latest from researchers in Denmark, observe that people ... lesser risk of developing dementia and Alzheimer's disease. People ... benefit. ,The researchers are realistic about their research. ...
... than a placebo when it comes to the relief of ... at the Mayo Clinic, the majority of people with muscle ... relieved// by ionized bracelets. So the researchers divided the participants ... ionized bracelet, while the other received a placebo bracelet that ...
... doing exercise improves your cholesterol profile, even in the ... shown how exercise affects the level of 'good' and ... the body attached to protein molecules, the combination being ... (LDL or 'bad' cholesterol) are linked to heart disease, ...
... person aged 40 or over has a lifetime risk of ... they have high blood pressure. Heart failure is an increasing ... within the heart which makes it hard to pump blood ... the condition is very disabling. ,Researchers for the ...
... survival of criticare patients gets better if specialists in ... Hopkins and Pittsburgh University have analysed the evidence on ... found that patients do much better if they are ... in critical care medicine. ,Previous research has ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: